Amrutanjan Health Care profit and loss

Latest FY26

Revenue: ₹503cr+11.2% on FY25
EBITDA: ₹75.7cr+30.0% on FY25
Net profit: ₹57.9cr+13.9% on FY25
EPS: ₹20.03+13.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	511	503	452	421	380	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	17.0	17.6	17.7	16.9	14.5
	528	520	469	438	394
	111	106	101	103	105
	146	141	123	106	78.5
	−7.2	−2.7	−0.6	2.2	−1.7
	65.4	63.8	59.1	48.3	48.8
	0.2	0.2	0.2	0.2	0.1
	6.7	6.3	6.5	6.1	5.2
	123	119	111	110	104
	445	433	400	376	341
	73.5	75.7	58.2	51.2	44.4
	66.8	69.4	51.7	45.2	39.2
Profit
	83.5	86.7	69.1	61.9	53.6
	−10.9	−8.9	0.0	0.0	0.0
	72.7	77.9	69.1	61.9	53.6
	18.7	20.0	18.3	15.9	14.0
	0.0	0.0	0.0	1.0	−0.2
	18.7	20.0	18.3	17.0	13.8
	54.0	57.9	50.8	45.0	39.8
	54.0	57.9	50.8	45.0	39.8
	−0.4	−0.1	−0.8	0.2	−1.2
	53.5	57.8	50.0	45.1	38.6
Per share
	₹18.67	₹20.03	₹17.58	₹15.56	₹13.65
	₹18.67	₹20.03	₹17.58	₹15.56	₹13.63
Other comprehensive income — detail
	−0.4	−0.1	−0.8	—	—
	−0.6	−0.2	−1.1	0.2	−1.6
	−0.1	−0.0	−0.3	—	—
	—	—	—	0.1	−0.4
Per share — as-filed variants
	₹18.67	₹20.03	₹17.58	₹15.56	₹13.65
	₹18.67	₹20.03	₹17.58	₹15.56	₹13.63
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	262	258	229	209	198
	51.3%	51.4%	50.6%	49.7%	52.1%
Adjusted (ex-exceptional items) — derived
	83.5	86.7	69.1	61.9	53.6
	−10.9	−8.9	0.0	0.0	0.0
	62.1	64.5	50.8	45.0	39.8
	₹21.47	₹22.31	₹17.58	₹15.56	₹13.65

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AMRUTANJAN₹493.00

Amrutanjan Health Care Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersJAGSNPHARM NGLFINE SIGACHI LINCOLN SYNCOMF THEMISMED HESTERBIOMcap ₹1,425 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	379.6	421.2	451.8	502.6	511.5
Other Income	14.5	16.9	17.7	17.6	17.0
Total Income	394.2	438.2	469.5	520.1	528.4
Expenses
+ Cost of Materials Consumed	105.2	103.4	100.6	106.4	110.9
+ Purchases of Stock-in-Trade	78.5	106.3	123.2	140.6	145.5
+ Changes in Inventories	-1.7	2.2	-0.6	-2.7	-7.2
+ Employee Benefit Expense	48.8	48.3	59.1	63.8	65.4
+ Finance Costs	0.1	0.2	0.2	0.2	0.2
+ Depreciation & Amortisation	5.2	6.1	6.5	6.3	6.7
+ Other Expenses	104.5	109.9	111.3	118.7	123.4
Total Expenses	340.5	376.2	400.4	433.4	444.9
EBITDA	44.4	51.2	58.2	75.7	73.5
EBIT	39.2	45.2	51.7	69.4	66.8
Profit
PBT before Exceptional Items	53.6	61.9	69.1	86.7	83.5
+ Exceptional Items	0.0	0.0	0.0	-8.9	-10.9
Pretax Income	53.6	61.9	69.1	77.9	72.7
+ Current Tax	14.0	15.9	18.3	20.0	18.7
+ Deferred Tax	-0.2	1.0	0.0	0.0	0.0
Tax Expense	13.8	17.0	18.3	20.0	18.7
Net Income	39.8	45.0	50.8	57.9	54.0
+ Net Income — Continuing Ops	39.8	45.0	50.8	57.9	54.0
+ Other Comprehensive Income	-1.2	0.2	-0.8	-0.1	-0.4
Total Comprehensive Income	38.6	45.1	50.0	57.8	53.5
Per Share
Basic EPS	13.65	15.56	17.58	20.03	18.67
Diluted EPS	13.63	15.56	17.58	20.03	18.67
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.8	-0.1	-0.4
+ Items NOT to be Reclassified to P&L	-1.6	0.2	-1.1	-0.2	-0.6
+ Tax on Items NOT to be Reclassified	—	—	-0.3	-0.0	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.4	0.1	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	13.65	15.56	17.58	20.03	18.67
Diluted EPS — Continuing Operations	13.63	15.56	17.58	20.03	18.67
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	197.7	209.4	228.6	258.2	262.2
Gross Margin %	52.06	49.71	50.60	51.38	51.27
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	53.6	61.9	69.1	86.7	83.5
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-8.9	-10.9
Net Income Adj (tax-effected)	39.8	45.0	50.8	64.5	62.1
EPS Adj	13.65	15.56	17.58	22.31	21.47
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	2.9	2.9	2.9	2.9	2.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.